JACKSONVILLE, Fla.,
May 30, 2018 /PRNewswire/
-- TapImmune Inc. (NASDAQ: TPIV), a clinical-stage
immuno-oncology company, today announced that its President and
CEO, Peter Hoang, will participate
in a panel discussion and give a company presentation at the 2018
Sachs Associates Immuno-Oncology BD&L and Investment Forum,
held June 1, 2018 at the Waldorf
Astoria Chicago Hotel.
Immuno-Oncology BD&L and Investment
Forum
TapImmune Company Presentation
Date:
Friday, June 1, 2018
Time: 12:20 PM CT
Location: Track A
Advances in Cell and Gene Therapies Panel
Date: Friday, June 1, 2018
Time: 1:50 PM CT
Location: Track A
An audio webcast will be accessible via the News and Events
section of the TapImmune website: https://tapimmune.com/events. An
archive of the audio will remain available for 90 days following
the presentation.
About TapImmune Inc.
TapImmune Inc. is a leader in the
development of novel immunotherapies for cancer, with multiple
Phase 2 and Phase 1b/2 clinical
studies currently ongoing for the treatment of ovarian and breast
cancer. The company's peptide or nucleic acid-based
immunotherapeutic products comprise multiple naturally processed
epitopes (NPEs) that are designed to comprehensively stimulate a
patient's killer T cells and helper T cells, and to restore or
further augment antigen presentation using proprietary nucleic
acid-based expression systems. This unique approach can produce
off-the-shelf T cell vaccine candidates that elicit a broad-based T
cell response and can be used without respect to HLA type. The
company's technologies may be used as stand-alone medications or in
combination with other treatment modalities. TapImmune has
announced a proposed merger with Marker Therapeutics, Inc., a
privately-held clinical stage developer of a transformative,
non-genetically engineered, multi-antigen T cell therapy platform,
which will add a significant portfolio of clinical-stage cell
therapies to create a leading immuno-oncology pipeline.
For additional information, please visit:
https://tapimmune.com/
To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/
Follow us on Twitter @Tapimmune_Inc, or follow us on
Facebook.
For answers to frequently asked questions, please visit our FAQs
page:
https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release
contains forward-looking information within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this news release concerning the Company's expectations, plans,
business outlook or future performance, and any other statements
concerning assumptions made or expectations as to any future
events, conditions, performance or other matters, are
"forward-looking statements". Forward-looking statements are by
their nature subject to risks, uncertainties and other factors
which could cause actual results to differ materially from those
stored in such statements. Such risks, uncertainties and factors
include, but are not limited to the results of the Phase 2 clinical
trials, the ability to obtain regulatory approval of TPIV200, the
Company's ability to raise future financing for continued
development and the ability to successfully commercialize TPIV200
as well as the risks and uncertainties set forth in the Company's
most recent Form 10-K, 10-Q and other SEC filings which are
available through EDGAR at www.sec.gov. The Company assumes no
obligation to update the forward-looking statements.
View original content with
multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-2018-sachs-associates-immuno-oncology-bdl-and-investment-forum-300653980.html
SOURCE TapImmune Inc.
